Tubastatin A, an isoform-selective HDAC6 inhibitor, can mitigate hyperglycemia-provoked cardiac dysfunction, cardiac infarction, and free radical generation by facilitating the Prdx1 acetylation [53]. This evidence concerns the gene HDAC6 and Hyperglycemia.